Moreadith Randall, Chief Scientific Officer at SER, has been a consistent seller of company stock over the past year, with no open-market purchases recorded. Across 85 total Form 4 filings, Randall’s transactions amount to roughly $1.12 million in sales, all in SER shares, against a negligible $38.70 in acquired value. The pattern is unambiguous: every sale is paired with an option exercise or award, and the sales cluster tightly around those exercises, indicating a mechanical liquidation of vested equity rather than a directional bet on the stock.
The most recent activity, spanning December 2025 through March 2026, shows 12 separate open-market sales totaling approximately $238,000. The largest single sale came on March 19, 2026, when Randall sold $97,500 worth of SER stock, following an option exercise valued at $2,340. Smaller sales in January and February ranged from $2,713 to $34,953, each paired with modest option exercises. The final reported transaction, a grant on May 21, 2026, carried no dollar value, suggesting a routine compensation award.
Notably, Randall has not executed a single open-market purchase (code “P”) in the entire filing history, and the recent sales are all coded “S,” meaning they were executed on the open market rather than returned to the issuer. The absence of buys, combined with the steady cadence of sales tied to option exercises, points to a disciplined approach of converting equity compensation into cash. There is no evidence of concentrated selling pressure or a sudden shift in behavior—the pattern is consistent, periodic, and entirely one-directional.
AI-assisted summary